MODIFICATION
A -- The contractor shall provide intramural research studies and expertise in support of the ongoing pre-clinical development of PfE140 vaccine that is currently being conducted in the Malaria Department at the Naval Medical Research Center, Silver Spring, MD
- Notice Date
- 12/20/2017
- Notice Type
- Modification/Amendment
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- Department of the Navy, Bureau of Medicine and Surgery, Naval Medical Logistics Command, 693 Neiman Street, FT Detrick, Maryland, 21702-9203, United States
- ZIP Code
- 21702-9203
- Solicitation Number
- ADVFY18RD00003
- Archive Date
- 1/20/2018
- Point of Contact
- Cheryl Vendemia, Phone: 3016196004, Thomas L. Hood, Phone: 3016198894
- E-Mail Address
-
cheryl.r.vendemia.civ@mail.mil, thomas.l.hood26.civ@mail.mil
(cheryl.r.vendemia.civ@mail.mil, thomas.l.hood26.civ@mail.mil)
- Small Business Set-Aside
- N/A
- Description
- Sources Sought Notice The Naval Medical Logistics Command (NMLC) is seeking sources to provide intramural research studies and expertise in support of the ongoing pre-clinical development of PfE140 vaccine that is currently being conducted in the Malaria Department at the Naval Medical Research Center (NMRC), Silver Spring, MD. This procurement requires research expertise to review and provide guidance on the planning and conduct of the development of the PfE140 vaccine and antigen discovery projects. The PfE140 vaccine work will focus first on the systematic evaluation of several vaccine platforms and regimens to optimize the PfE140 vaccine efficacy. This extensive phase of the project will be followed by a series of studies aiming to increase the vaccine efficacy by combining PfE140 with PfCSP antigen. Finally, studies will be done to evaluate PfE140 cross-protection against one or more heterologous (different from the vaccine strain, such as Pf7G8) challenge parasite strains. This comprehensive approach will ensure the prioritization of the most efficacious PfE140 subunit vaccine establishing a path forward into Investigational New Drug (IND) filing and Phase 1 clinical trials. The work will also involve the generation of human monoclonal antibodies (Hu mAb) and continuation of the malaria antigen discovery project (to identify and characterize additional malaria antigens). The Malaria Department requires the technical and research support expertise for existing funded PfE140 vaccine development, Hu mAb generation, and malaria antigen discovery projects and to develop and apply for new grants to support malaria antigen discovery and vaccine development. This requirement involves building upon research conducted throughout the last years (2014-2017) under the CAMRIS International (CAMRIS) "Malaria Antigen Discovery" (MAD) contract W911QY-11-D-0063 Task Order 0002. Under this contract, CAMRIS researchers, led by Dr. Joao Aguiar, identified a novel highly protective mouse malaria pre-erythrocytic (PE) antigen, E140, which induced up to 100% sterile protection in outbred and inbred mice, alone or in combination with other antigens, which persisted for at least three months. The E140 protection levels are exceptionally high and unprecedented in malaria pre-clinical research. The aim of this study is to develop a P. falciparum vaccine lead candidate, E140, a novel pre-erythrocytic and erythrocytic vaccine candidate. The development of the PfE140 vaccine and antigen discovery projects cannot be possible without building upon the groundbreaking discovery of the Novel Antigen for use in Malaria (patent pending), which is vital to the ongoing-pre-clinical development of PfE140 vaccine. The use of any other source would cause substantial delays and disruption to the ongoing pre-clinical development of PfE140 vaccine. If capable sources are not identified through this notice, NMLC intends to award a sole source contract under the authority of FAR 6.302-1 to CAMRIS International, 3 Bethesda Metro Center, 16th Floor, Bethesda, MD 20814. The award is contingent upon CAMRIS providing the lead researcher, Dr. Joao Aguiar. This sources sought notice is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to perform the required work. Capability statements shall not exceed 1 (8.5 x 11 inch) page using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source contract. Capability statements are due by 12:30 PM Local Time, 20 December 2017. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to the following address: cheryl.r.vendemia.civ@mail.mil AND thomas.l.hood26.civ@mail.mil.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/DON/BUMED/N62645/ADVFY18RD00003 /listing.html)
- Place of Performance
- Address: 503 Robert Grant Avenue, Silver Spring, Maryland, 20910-7500, United States
- Zip Code: 20910-7500
- Zip Code: 20910-7500
- Record
- SN04772708-W 20171222/171220231400-6c90f87adda5e57aa480b3f5814e1cc1 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |